Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment
Executive Summary
The generic drug company will drive mid-term growth by investing in high-barrier-to-entry generics and biosimilars while diversifying into brand medicines and over-the-counter drugs. Management presented a strategy overview during an investor day March 1.
You may also be interested in...
Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Wixela Inhub could be the first interchangeable generic version of the blockbuster asthma drug on the US market if it is approved by FDA.
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
The latest drug development news and highlights from our FDA Performance Tracker.
Mylan Plans Workforce Reduction After M&A And Price Scandal
Mylan said it expects to cut less than 10% of its workforce under a restructuring to streamline operations following a series of acquisitions. The news comes amid a spate of negative publicity for the company, including a $465m settlement with the US Department of Justice over EpiPen.